It looks like Emergent BioSolutions' woes may not be restricted to the millions of vaccine doses it had to trash because of issues at its Baltimore-area plant. CEO Robert Kramer is now in the crosshairs over what ABC News calls a "weeks-long stock transaction" that netted him north of $7.6 million—a move made prior to the company's failings being made public. But the issues were known to Emergent, which by the time Kramer's stock deal wrapped up, had discarded ingredients that had been intended for millions of Johnson & Johnson doses over quality control issues; millions of doses' worth of AstraZeneca's vaccine had also been ditched. More on the current state of the company, which landed a $628 million federal vaccine contract last June:
- CNN has a timeline and specifics: Kramer sold just shy of 100,000 shares Jan. 15 and Feb. 26. The average share price works out to be $113.73. It closed at $63.13 on Thursday. Had Kramer not sold, the value of the shares would be down about $5 million. The Washington Post calls it Kramer's "first substantive sales of Emergent stock since April 2016."